Carboplatin AUC 5

DRUG3 trials

Sponsors

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Hao Long, CatalYm GmbH

Conditions

Adult Solid TumorBiomarkerChemotherapyMetastatic Non-Squamous Non-Small Cell Lung CancerPleural Mesothelioma MalignantSafetyTislelizumab

Phase 2

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

CompletedNCT04177953

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestPleural Mesothelioma Malignant

Start: 2019-02-04End: 2025-01-30Updated: 2025-02-06

Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC

Hao LongBiomarker, Chemotherapy, Safety +1

Start: 2020-12-22End: 2023-12-31Target: 100Updated: 2022-02-17

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

RecruitingNCT07098988

CatalYm GmbHAdult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer

Start: 2025-08-01End: 2031-03-31Target: 107Updated: 2026-02-27

Related Papers

Baseline multi-omics signatures could predict therapeutic response to neoadjuvant anti-PD-1 immunochemotherapy in non-small-cell lung cancer.

2026-01-01

Nivolumab with chemotherapy in pleural mesothelioma after surgery: The NICITA trial.

Journal of Clinical Oncology2023-06-011 citations

Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).

Journal of Clinical Oncology2023-06-011 citations

A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.

2020-10-1412 citations